Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

被引:7
|
作者
Watase, Mayuko [1 ]
Mochimaru, Takao [1 ,2 ]
Kawase, Honomi [1 ]
Shinohara, Hiroyuki [1 ]
Sagawa, Shinobu [1 ]
Ikeda, Toshiki [1 ]
Yagi, Shota [1 ]
Yamamura, Hiroyuki [1 ]
Matsuyama, Emiko [1 ]
Kaji, Masanori [1 ]
Kurihara, Momoko [1 ]
Sato, Midori [1 ]
Horiuchi, Kohei [1 ]
Watanabe, Risa [1 ]
Nukaga, Shigenari [1 ]
Irisa, Kaoru [1 ]
Satomi, Ryosuke [1 ]
Oyamada, Yoshitaka [1 ,2 ]
机构
[1] Natl Hosp Org Tokyo Med Ctr, Dept Resp Med, Tokyo, Japan
[2] Natl Hosp Org Tokyo Med Ctr, Dept Allergy, Tokyo, Japan
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
PULMONARY-FIBROSIS;
D O I
10.1371/journal.pone.0283288
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
No biomarkers have been identified in bronchoalveolar lavage fluid (BALF) for predicting fibrosis progression or prognosis in progressive fibrosing interstitial lung disease (PF-ILD). We investigated BALF biomarkers for PF-ILD diagnosis and prognosis assessment. Overall, 120 patients with interstitial pneumonia who could be diagnosed with PF-ILD or non PF-ILD were enrolled in this retrospective study. PF-ILD was diagnosed according to Cottin's definition. All patients underwent bronchoscopy and BALF collection. We evaluated blood and BALF parameters, high-resolution computed tomography (HRCT) patterns, and spirometry data to identify factors influencing PF-ILD diagnosis and prognosis. On univariate logistic analysis, age, sex, the BALF white blood cell fraction (neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio), BALF flow cytometric analysis (CD8), and an idiopathic pulmonary fibrosis/usual interstitial pneumonia pattern on HRCT were correlated with PF-ILD diagnosis. Multivariate logistic regression analysis revealed that sex (male), age (cut-off 62 years, area under the curve [AUC] 0.67; sensitivity 0.80; specificity 0.47), white blood cell fraction in BALF (NLR, neutrophil, and lymphocyte), and CD8 in BALF (cut-off 34.2; AUC 0.66; sensitivity, 0.74; specificity, 0.62) were independent diagnostic predictors for PF-ILD. In BALF, the NLR (cut-off 8.70, AUC 0.62; sensitivity 0.62; specificity 0.70), neutrophil count (cut-off 3.0, AUC 0.59; sensitivity 0.57; specificity 0.63), and lymphocyte count (cut-off 42.0, AUC 0.63; sensitivity 0.77; specificity 0.53) were independent diagnostic predictors. In PF-ILD patients (n = 77), lactate dehydrogenase (cut-off 275, AUC 0.69; sensitivity 0.57; specificity 0.78), Krebs von den Lungen-6 (cut-off 1,140, AUC 0.74; sensitivity 0.71; specificity 0.76), baseline forced vital capacity (FVC) (cut-off 1.75 L, AUC 0.71; sensitivity, 0.93; specificity, 0.46), and BALF neutrophil ratio (cut-off 6.0, AUC 0.72; sensitivity 0.79; specificity 0.80) correlated with death within 3 years. The BALF cellular ratio, particularly the neutrophil ratio, correlated with the diagnosis and prognosis of PF-ILD. These findings may be useful in the management of patients with interstitial pneumonia.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Acute exacerbation of progressive fibrosing interstitial lung disease: Incidence and outcomes
    Yang, Jiyoul
    Song, Jin Woo
    RESPIROLOGY, 2023, 28 : 59 - 60
  • [32] Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
    Nasser, Mouhamad
    Larrieu, Sophie
    Si-Mohamed, Salim
    Ahmad, Kais
    Boussel, Loic
    Brevet, Marie
    Chalabreysse, Lara
    Fabre, Celine
    Marque, Sebastien
    Revel, Didier
    Thivolet-Bejui, Francoise
    Traclet, Julie
    Zeghmar, Sabrina
    Maucort-Boulch, Delphine
    Cottin, Vincent
    EUROPEAN RESPIRATORY JOURNAL, 2021, 57 (02)
  • [33] Progressive Fibrosing Interstitial Lung Disease A Proposed Integrated Algorithm for Management
    Varone, Francesco
    Sgalla, Giacomo
    Iovene, Bruno
    Richeldi, Luca
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (10) : 1199 - 1203
  • [34] Editorial: Progressive fibrosing interstitial lung disease: from bench to bedside
    Guiot, Julien
    Njock, Makon-Sebastien
    FRONTIERS IN MEDICINE, 2023, 10
  • [35] Efficacy of Antifibrotic Treatments in Patients with Progressive Fibrosing Interstitial Lung Disease
    Sugino, K.
    Ono, H.
    Saito, M.
    Ando, M.
    Tsuboi, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [36] Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry
    Hambly, Nathan
    Farooqi, M. Malik
    Dvorkin-Gheva, Anna
    Donohoe, Kathryn
    Garlick, Kristopher
    Scallan, Ciaran
    Chong, Sy Giin
    MacIsaac, Sarah
    Assayag, Deborah
    Johannson, Kerri A.
    Fell, Charlene D.
    Marcoux, Veronica
    Manganas, Helene
    Morisset, Julie
    Comes, Alessia
    Fisher, Jolene H.
    Shapera, Shane
    Gershon, Andrea S.
    To, Teresa
    Wong, Alyson W.
    Sadatsafavi, Mohsen
    Wilcox, Pierce G.
    Halayko, Andrew J.
    Khalil, Nasreen
    Cox, Gerard
    Richeldi, Luca
    Ryerson, Christopher J.
    Kolb, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60 (04)
  • [37] Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
    Fischer, Aryeh
    Distler, Joerg
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2673 - 2681
  • [38] Budget impact analysis of tocilizumab in progressive fibrosing interstitial lung disease
    Ashraf, Amirul
    Ong, Siew C.
    MINERVA RESPIRATORY MEDICINE, 2023, 62 (03): : 101 - 107
  • [39] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Fabre, Aurelie
    Nicholson, Andrew G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (08): : 780 - 780
  • [40] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Walsh, S. L. F.
    Inoue, Y.
    Richeldi, L.
    Kolb, M.
    Tetzlaff, K.
    Stowasser, S.
    Coeck, C.
    Clerisme-Beaty, E.
    Rosenstock, B.
    Quaresma, M.
    Haeufel, T.
    Goeldner, R-G
    Schlenker-Herceg, R.
    Brown, K. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18): : 1718 - 1727